熱門資訊> 正文
尽管有Pemgarda COVID风险降低数据,Invivyd仍下跌18%
2024-08-28 00:59
- Patients treated with Invivyd's (NASDAQ:IVVD) Pemgarda (pemibivart) showed an 84% relative risk reduction in symptomatic COVID-19 compared to placebo in a phase 3 trial.
- In a group of all-comer immunocompetent individuals, 1.9% of treated individuals in a 180-day time period developed symptomatic COVID. compared to 11.9% in the placebo group.
- Pemgarda currently has Emergency Use Authorization from the U.S. FDA for COVID pre-exposure prophylaxis.
- Despite the results, shares are off 18%.
More on Invivyd
- Invivyd, Inc. (IVVD) Q2 2024 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on Invivyd
- Historical earnings data for Invivyd
- Financial information for Invivyd
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。